Paper Details

  1. Home
  2. Paper Details

Synthesis, cytotoxicity assay, pharmacokinetics, biodistribution and modeling study of cabazitaxel-dextran nanoconjugates: targeted vs non targeted delivery.

Author: AhmadiFatemeh, DaneshamouzSaeid, ParhizkarElahehnaz, ParhizkarGolnaz, SakhtemanAmirhossein, SamaniSoliman Mohammadi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Cabazitaxel (CTX), a second-generation taxane derivative, is used for cancer treatment, but its current formulation causes hypersensitivity reactions due to high surfactant and ethanol content. This study investigated the development of folate-containing prodrugs for CTX delivery. The researchers synthesized dextran and dextran-folate nanoconjugates, finding that folate conjugates exhibited higher cytotoxicity and enhanced pharmacokinetic properties, including increased area under the curve and longer half-life, compared to free CTX. The findings suggest that prodrugs could offer a safer and more effective alternative to the current CTX formulation.
Paper Details　
Original Abstract of the Article :
Cabazitaxel (CTX) is an anti-neoplastic agent of second-generation taxane derivatives, characterized by very low water solubility. The currently marketed formulation of CTX contains high concentrations of surfactant and ethanol, which causes severe hypersensitivity reactions in patients. To deal wit...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.colsurfb.2021.112187

データ提供：米国国立医学図書館（NLM）

Cabazitaxel-Dextran Nanoconjugates: Targeted Delivery of Cancer Therapy

The fight against cancer is a relentless journey, akin to a camel traversing a vast and unforgiving desert. This study explores the potential of cabazitaxel-dextran nanoconjugates, a novel approach to delivering chemotherapy directly to cancer cells. The authors investigated the synthesis, cytotoxicity, pharmacokinetics, and biodistribution of these nanoconjugates, comparing targeted delivery with non-targeted delivery. Their findings shed light on the potential of this innovative approach to cancer therapy.

Targeted Delivery: A Precise Strike Against Cancer

The study demonstrated that folate-containing nanoconjugates exhibited higher toxicity against cancer cells compared to non-targeted dextran nanoconjugates. Furthermore, in vivo studies revealed that these nanoconjugates displayed enhanced pharmacokinetic properties, leading to increased serum residence time and tissue accumulation in the liver, the primary target organ for cabazitaxel. These findings suggest that targeted delivery of cabazitaxel-dextran nanoconjugates could be a more effective and less toxic approach to cancer therapy.

Health Implications and Practical Applications

This research presents a promising new strategy for delivering chemotherapy, potentially reducing side effects and improving treatment efficacy. While further clinical trials are needed to confirm its safety and effectiveness, this study offers a glimpse into the future of cancer therapy, where targeted delivery could revolutionize the fight against this devastating disease.

Dr. Camel's Conclusion

This study highlights the potential of nanotechnology in cancer therapy. By harnessing the power of targeted delivery, researchers are seeking to improve the efficacy and reduce the toxicity of chemotherapy. Just as a camel uses its adaptations to navigate the harsh desert, researchers are exploring innovative ways to overcome the challenges of cancer treatment. This research serves as a reminder that we must embrace scientific advancements to find new solutions to the complex problems facing humanity.

Date :
  1. Date Completed 2021-12-14
  2. Date Revised 2021-12-14
Further Info :

Pubmed ID

34837858

DOI: Digital Object Identifier

10.1016/j.colsurfb.2021.112187

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.